Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 109Leukemia, Myeloid, Acute 102Leukemia 97Myelodysplastic Syndromes 87Precursor Cell Lymphoblastic Leukemia-Lymphoma 74Lymphoma, Non-Hodgkin 71Lymphoma 71Multiple Myeloma 70Hodgkin Disease 68Lymphoma, Mantle-Cell 53Lymphoma, Follicular 51Lymphoma, Large B-Cell, Diffuse 50Leukemia, Myelogenous, Chronic, BCR-ABL Positive 45Lymphoma, B-Cell, Marginal Zone 44Myeloproliferative Disorders 43Congenital Abnormalities 41Burkitt Lymphoma 37Leukemia, Myelomonocytic, Chronic 36Waldenstrom Macroglobulinemia 32Leukemia, Myeloid, Accelerated Phase 32Primary Myelofibrosis 31Melanoma 31Lymphoma, Large-Cell, Immunoblastic 31Leukemia, Myeloid, Chronic-Phase 31Blast Crisis 28Recurrence 27Neoplasms, Plasma Cell 25Hematologic Neoplasms 24Lymphoma, T-Cell, Cutaneous 23Dendritic Cell Sarcoma, Interdigitating 23

Interventions

Imatinib Mesylate 5nilotinib 4bosutinib 3asciminib 2peginterferon alfa-2a 1fludarabine phosphate 1fludarabine 1Magnetic Resonance Imaging 1Electrocardiography 1Echocardiography 1Diphenhydramine 1Dasatinib 1Cyclophosphamide 1Blood Component Removal 1Antiemetics 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Philadelphia Chromosome × fludarabine phosphate × Clear all
NCT03448393 2025-06-04

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
54 enrolled 24 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Philadelphia Chromosome, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡